US panel review for Savient's gout therapy pegloticase
This article was originally published in Scrip
Executive Summary
The US FDA's arthritis advisory committee will meet on March 5th to consider Savient Pharmaceuticals' pegloticase for treatment-failure gout. The BLA has orphan designation and is undergoing a priority review, with a user fee date of April 30th.